Annonce • Jun 19
Elicera Therapeutics AB Receives Positive Feedback From Swedish MPA On Planned Clinical Study With ELC-401 In Grade IV Glioma Elicera Therapeutics AB held a scientific advice meeting with the Swedish Medical Products Agency (MPA) regarding the planned first-in-human clinical study of ELC-401, the company's iTANK-armed CAR T-cell candidate targeting IL13Ra2 in grade IV glioma. During the meeting, Elicera presented its proposed trial design and received supportive and constructive regulatory guidance from the MPA regarding the clinical protocol, dose-escalation strategy, and product manufacturing specifications. The agency confirmed that the submitted preclinical data package is considered sufficient to support the initiation of clinical development. Glioblastoma is the most aggressive primary brain tumor, with a median survival of approximately 15 months despite standard treatments (surgery, radiotherapy, and chemotherapy). ELC-401 is designed to target IL13Ra2-positive tumors while using the iTANK platform to stimulate endogenous immune responses against additional tumor antigens, potentially overcoming heterogeneity and immunosuppression in GBM. The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. Annonce • Jun 09
Elicera Therapeutics AB (Publ) Announces Stepping Down of Agneta Edberg as Chair Elicera Therapeutics AB (publ) announced that Agneta Edberg, who has served as Chair since 2021, wished to step down from the Chair position but is standing for re-election as an ordinary board member. New Risk • Jun 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr23m net loss in 2 years). Revenue is less than US$5m (kr11m revenue, or US$1.1m). Market cap is less than US$100m (€17.9m market cap, or US$20.8m). Annonce • May 23
Elicera Therapeutics AB (publ), Annual General Meeting, Jun 25, 2026 Elicera Therapeutics AB (publ), Annual General Meeting, Jun 25, 2026, at 13:00 W. Europe Standard Time. Location: advokatfirman delphi, master samuelsgatan 17, stockholm Sweden Annonce • May 15
Elicera Therapeutics AB (publ) Announces Executive Changes Elicera Therapeutics AB (publ) announced that the Company's co-founder, Chief Scientific Officer (CSO) and board member Professor Magnus Essand is taking temporary leave from his duties in the Company in order to undergo medical treatment. Di Yu is appointed Acting CSO. Di Yu has, in recent years, held the greatest operational responsibility for the Company's scientific and clinical development. He has been deeply involved in the day-to-day management of the research and development programs. Magnus Essand has played a central role in the planning and design of the CARMA study (ELC-301) and the planned glioblastoma study (ELC-401). These study designs are now finalized, which is why Magnus Essand's operational involvement has gradually decreased thereafter. To ensure continuity and progress in the business, Di Yu has temporarily taken over the role of Acting Chief Scientific Officer (CSO) with immediate effect. Annonce • Apr 22
Elicera Therapeutics AB (publ), Annual General Meeting, May 08, 2026 Elicera Therapeutics AB (publ), Annual General Meeting, May 08, 2026, at 13:00 W. Europe Standard Time. Location: advokatfirman delphi, master samuelsgatan 17, stockholm Sweden Annonce • Apr 21
Elicera Therapeutics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 72.803316 million. Elicera Therapeutics AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 72.803316 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 24,267,772
Price\Range: SEK 3
Transaction Features: Rights Offering Annonce • Mar 11
Elicera Therapeutics AB Receives Notice of Allowance for Japanese Patent Protecting the ELC-401 CAR T-Cell Candidate Elicera Therapeutics AB (publ) received a Notice of Allowance from the Japan Patent Office regarding its patent application for the CAR T-cell candidate ELC-401. Once the patent has been granted, it can be maintained in force until 2041. The patent protects Elicera's special antibodies that recognize and bind to the protein IL-13Ra2 (which is often present in large quantities on cancer cells, particularly brain tumors), as well as uses thereof in cancer treatment, such as CAR-T cell therapies. The patent gives Elicera exclusive rights in Japan to develop and sell treatments based on these anti-IL-13Ra2 antibodies and related technologies for cancer treatment. This strengthens the company's protection for ELC-401 (its CAR-T cell candidate against glioblastoma) and other future products based on the same principle. Annonce • Mar 06
Elicera Therapeutics AB Provides an Update on the Ongoing Phase I/Iia Carma Study Elicera Therapeutics AB provided an update on the ongoing Phase I/IIa CARMA study evaluating its lead CAR T-cell therapy candidate ELC-301 in patients with relapsed or refractory B-cell lymphoma. New data shows complete metabolic responses from the first two patients treated in cohort 3 (the highest dose level to date), as well as follow-up data from patients in cohorts 1 and 2. These results will be presented by the Company's Chief Scientific Officer, Professor Magnus Essand, during an invited scientific presentation at the 10th Zurich Immuno-Oncology Conference 2026 in Zürich, Switzerland. The CARMA study is a Phase I/IIa clinical trial assessing the safety, optimal dosing, and preliminary efficacy of ELC-301 in patients with relapsed or refractory B-cell lymphoma. It includes a dose-escalation phase (Phase I) across three cohorts to identify the maximum tolerated dose, followed by further evaluation in an expansion phase (Phase IIa). Key highlights from the data: Both patients so far treated in cohort 3 achieved a complete metabolic response (CMR), meaning no detectable active disease/patients were disease-free - at the one-month follow-up assessment. No dose-limiting toxicities (DLTs) were observed, and the treatment was well tolerated across cohorts. Across the 8 patients treated to date: Disease control rate: 100%. Overall response rate (ORR): 7/8. CMR at month 1: 6/8. Of the 6 patients with confirmed CMR at month 1, 4 had sustained CMR at their last recorded follow-up. The best responses have so far been confirmed lasting up to at least 12 months. The early positive signals from the highest dose cohort adds to the previous updates showing CMR in four of six patients in the first two cohorts (lower dose levels), with a favorable safety profile and no DLTs observed to date. The CARMA study continues to progress as planned, recruitment now ongoing in cohort 3 (targeting six patients total). ELC-301 is an iTANK-armed CAR T-cell therapy designed to target the CD20 antigen on B-cells while leveraging the proprietary iTANK platform to stimulate a broader, parallel immune response against cancer cells. Annonce • Feb 27
Elicera Therapeutics AB (publ) Provides Update on Preclinical CAR T-Cell Program ELC-401 for Glioblastoma Elicera Therapeutics AB (publ) provides an update on the development of its iTANK-armed CAR T-cell therapy candidate ELC-401 for the treatment of recurrent glioblastoma, an aggressive form of brain cancer with significant unmet medical need. ELC-401 is an iTANK-armed CAR T -cell therapy targeting the tumor antigen IL13Ra2, which is overexpressed in most glioblastoma tumors. The program leverages Elicera's iTANK technology to enhance CAR T-cell efficacy by promoting a broader immune response against the immunosuppressive tumor microenvironment characteristic of solid tumors like glioblastoma. Preclinical development of ELC-401 has been successfully concluded. Through preclinical studies, the company has determined that local administration of CAR-T cells represents the optimal route of delivery to overcome the blood-brain barrier (BBB) and ensure effective CAR T-cell targeting to tumors in the brain. Elicera has advanced toward clinical development with a planned phase I/Ib dose-escalation/expansion trial. The proposed study design includes: Enrollment of 12 patients across four arms (three patients per arm), phase Ia. Two dose levels (low and high), with repeated CAR T-cell dosing in all arms. In parallel, Elicera is currently conducting process development studies to establish a robust and efficient manufacturing process that ensures high-quality CAR T-cells in appropriate formulations suitable for clinical use. Following this, a technology transfer to a selected manufacturer will be required. Assuming alignment on the study design with the MPA and successful completion of these manufacturing-related activities, the clinical trial could potentially commence during the second half of 2027. Elicera is actively pursuing several opportunities to secure non-dilutive ("soft") funding through grant applications from various sources. Responses to these applications are expected throughout 2026 and will hopefully help support the funding of the planned clinical trial for ELC-401. ELC-401 is designed to target IL13Ra2-positive tumors while using the iTANK platform to stimulate endogenous immune responses against additional tumor antigens, potentially overcoming heterogeneity and immunosuppression in GBM. About the iTANK platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled "CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers" (DOI number: 10.103838-positive tumors. Annonce • Feb 12
Elicera Therapeutics AB Announces Abstract Acceptance at ISCT 2026 Dublin Elicera Therapeutics AB (publ) announced that an abstract presenting data from the ongoing Phase I/IIa CARMA study has been accepted for presentation at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting in Dublin, Ireland, taking place May 6-9, 2026. The poster presentation will highlight complete metabolic response in four of six patients treated with the iTANK-armed CAR T-cell therapy ELC-301 in the first two cohorts of the study. ISCT brings together leading researchers, clinicians, and industry experts in cell and gene therapy from around the world. The primary goal of the conference is to facilitate the exchange of new scientific advancements, technological innovations, and clinical insights in the rapidly evolving field of cell and gene therapy. CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy E LC-301 in the treatment of patients with B-cell lymphoma. The study is dividend into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third dcohort, who are expected to receive the maximum tolerated dose. ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company's iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient's T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen--a molecule visible on the surface of cancer cells--and enables the T-cells to locate, bind to, and destroy the cancer cells. The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. Annonce • Jan 09
Elicera Therapeutics Announces Final Data from its Phase I/IIa Trial Demonstrating A Favorable Safety Profile and Promising Efficacy Signals of Oncolytic Virus ELC-100 in Neuroendocrine Tumors Elicera Therapeutics AB (publ) announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases. The study demonstrates that ELC-100, was generally well-tolerated with no dose-limiting toxicities observed. Importantly, the trial also revealed promising efficacy signals, including partial tumor responses in two out of eight patients evaluable for efficacy, providing early evidence of anti-tumor activity in this highly treatment-resistant population. Safety results: ELC-100 (formerly referred to as AdVince) was generally well-t tolerated, with no dose-limitingoxicities (DLTs) observed in any of the 12 treated patients. The safety profile was consistent with the expected mechanism of action of an oncolytic virus, characterized by a manageable inflammatory response. Maximum tolerated dose was established at 1 x 1012 virus particles as the highest tested dose. Notably, in this highly challenging patient population, consisting of individuals with advanced, end-stage Neuroendocrine tumors who had eliminated all currently available treatment options, promising preliminary signals of clinical efficacy were observed. Specifically, partial responses in 2 of 8 efficacy-evaluable patients. Twelve weeks after the 4thtreatment cycle, 75% of efficacy-evaluable patients (n=8) remained progression free. The clinical Phase I/IIa-study "Study of Recombinant Adenovirus AdVince in Patients with Neuroendocrine Neoplasms; Safety and Efficacy", enrolled 12 patients in total, in four escalating dose groups. Patients in each dose group received up to eight repeating doses of AdVince via hepatic artery infusion or intra-tumoral injection, with the primary objective of evaluating safety and determining maximum tolerated dose. Secondary objectives include to evaluate the anti-tumoral efficacy of AdVince infusions on metastatic neuroendocrine tumors and to determine the number of patients with progression-free-survival (PFS) twelve weeks after the 4thtreatment cycles. Efficacy population (n=8): All patients who had received at least one treatment period (four treatment cycles) of investigational product (AdVince, ELC-100) and had both baseline and evaluation of CT data (at the 1-month follow-up visit). Annonce • Sep 20
Elicera Therapeutics AB (Publ) Confirms Status of the iTANK -Platform Patent Application in the U.S Elicera Therapeutics AB (publ) clarifies that the ongoing patent application for the company's iTANK platform in the United States is still under examination by the United States Patent and Trademark Office (USPTO). The Board of Appeals at the United States Patent and Trad trademark Office (USPTO) issued a decision on September 8, 2025, regarding the company's appeal of the examiner's decision to reject the patent claims in the U.S. patent application concerning the company's iTANK platform. The Board of Appeals chose to uphold the examiner's decision to reject The patent claims. Annonce • Aug 25
Elicera Therapeutics AB (publ) Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee's Assessment in Cohort 2 Elicera Therapeutics AB (publ) announced that the Data Safety and Monitoring Board (DSMB) has completed its second assessment of the ongoing Phase I/IIa CARMA clinical study with the CAR T-cell therapy, ELC-301, for the treatment of B-cell lymphoma. The DSMB recommended the continuation of the study as planned. The dose-escalation study, conducted in collaboration with Uppsala University as the sponsor, consists of two parts: a dose-escalation study (Phase I) with 12 patients and a dose-expansion study (Phase IIa) with 6 patients. The cell therapy ELC-301 incorporates the iTANK platform technology, which, through its parallel immune activation, aims to provide a broader and more effective attack on cancer cells. The latest data report from the CARMA study, presented at the 7th Swedish Cancer Research Meeting in Malmo on May 22, showed promising preliminary results from the first dose cohort. Of the three patients treated with the lowest dose level, equivalent to one-tenth of the planned maximum dose, two achieved a complete metabolic response, meaning no active lymphoma was detected in imaging-based scans. This includes one patient who had previously stopped responding to a CD19-targeted CAR T therapy, reinforcing ELC-301's potential, particularly for this difficult-to-treat patient group. Following the Data Safety and Monitoring Board's (DSMB) recommendation to continue the study, treatment of patients in the third and final cohort with the highest dose level in the dose-escalation study can now commence. CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. the study is dividend into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. CAR T-cells are a form of cell therapy created by genetically modifying a patient's T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen-a molecule visible on the surface of cancer cells-and enables the T-cells to locate, bind to, and destroy the cancer cells. The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. Annonce • Jun 11
Elicera Therapeutics AB (publ) Announces Final Reporting of ELC-100 Study Due to Database Transition Elicera Therapeutics AB (publ) announced that the final reporting from the dose-escalation study with the drug candidate ELC-100 has been delayed. The plan was to report data during the summer, but based on new information from the contract research organization (CRO) responsible for the study's database and analysis, the study results are now expected to be reported before the end of 2025. Annonce • May 22
Elicera Therapeutics AB (publ) Announces Preliminary Data from the First Patient Cohort in the Ongoing Phase I/IIa Carma Study with iTANK-Aranded CAR T-Cell Therapy Elicera Therapeutics AB (publ) announced that preliminary principal investigator-assessed outcomes from the first patient cohort in the ongoing Phase I/IIa CARMA study with ELC-301 will be presented at the Swedish Cancer Research Meeting (SCRM) in Malmo, Sweden. Preliminary data show that two out of three treated patients had no active lymphoma detected on specializedscans, achieving a complete metabolic response. The CARMA study is evaluating ELC-301, an iTANK-armed CD20-targeting CAR T-cell therapy, in patients with relapsed or refractory B-cell lymphoma. The first dose cohort consisted of three patients treated with the lowest dose level, equivalent to one-tenth of the planned maximum dose. Professor Magnus Essand, Chief Scientific Officer and co-founder of Elicera Therapeutics, will present the data at the SCRM in Malmo, Sweden. Highlights from the preliminary principal investigator-ass assessed outcomes include: Patient 1, achieved complete metabolic response at one-month assessment, and the response remained at the six-month follow-up. Patient 2, who had previously received standard CD19 CAR T-cell therapy, had possible progression at the three-month follow-up, to be confirmed. Patient 3, also previously treated with CD19 CAR T therapy, achieved a complete metabolic response at the one-month follow-up. The CARMA study is continuing with patient enrollment at escalating dose levels to further assess safety, tolerability, and preliminary efficacy. Cohort 2 has already been initiated, with two patients treated so far at a dose level that is three times higher than that of Cohort 1. Additional preliminary data from this and subsequent cohorts will be reported as the study progresses and in connection with presentation at scientific conferences. CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. the study is divided into a dose-escalation phase (phase I) and a dose-exp expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third dcohort, who are expected to receive the maximum tolerated dose. The CARMA study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge. ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company's iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient's T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen--a molecule visible on the surface of cancer cells--and enables the T-cells to locate, bind to, and enables the T-cells to locating, bind to, and the immune response against cancer. Annonce • Apr 10
Elicera Therapeutics AB (Publ) Continues the Phase I/Iia Carma Study with Its Car T-Cell Therapy as Planned Following the Safety Committee's Assessment of Cohort 1 Elicera Therapeutics AB (publ) announced that the Data Safety and Monitoring Board (DSMB) has completed its first assessment of the ongoing Phase I/IIa CARMA clinical trial with the CAR T-cell therapy ELC-301 for the treatment of B-cell lymphoma. The DMSB recommended that the study continue as planned. The dose-escalation study, conducted in collaboration with Uppsala University as sponsor, previously reported a complete response (no detectable tumor) in the first treated patient at the initial follow-up one month after completing treatment, with no serious adverse events observed. Two additional patients have since been treated at the lowest dose level in the first dosing group (cohort 1). Elicera intends to report preliminary results from the study as each dosing cohort is completed. Preliminary efficacy data from the first cohort is expected to be presented at the 7th Swedish Cancer Research Meeting in Malmo on May 22. Following the DSMB's recommendation to proceed, treatment of patients in the second cohort at next dose level can now begin. CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapyELC-301 in the treatment of patients with B-cell lymphoma. the study is divided into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. Phase I is planned to include three cohorts (dosing groups), with three patients in the first and second cohorts, and six patients in the third dcohort, who are expected to receive the maximum tolerated dose. ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company's iTANK platform to activate a broader and more comprehensive parallel immune response against cancer. CAR T-cells are a form of cell therapy created by genetically modifying a patient's T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen--a molecule visible on the surface of cancer cells--and enables the T-cells to locate, bind to, and destroy the cancer cells. The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. Annonce • Apr 02
Elicera Therapeutics AB (publ), Annual General Meeting, May 15, 2025 Elicera Therapeutics AB (publ), Annual General Meeting, May 15, 2025, at 13:00 W. Europe Standard Time. Location: at the law firm delphias offices, mastersamuelsgatan 17, stockholm Sweden Annonce • Feb 10
Elicera Therapeutics AB (publ) Presents Initial Clinical Data from the CARMA Study At ISCT 2025 in New Orleans Elicera Therapeutics AB (publ) announced that the company will participate in the scientific conference International Society for Cell & Gene Therapy (ISCT) Meeting 2025 in New Orleans, USA, taking place from May 7 to May 10. At the conference, the company will present initial data from the ongoing clinical Phase I/IIa CARMA study, which show complete tumor remission in the first patient one month after treatment. Margareth Jorvid, regulatory expert and board member of Elicera Therapeutics, will participate in a networking session to present the company's scientific poster titled "iTANK Platform-Derived CAR20(NAP)-T Cell For Lymphoma: Complete Remission Data Reported For First Patient." ISCT brings together leading researchers, clinicians, and industry experts in cell and gene therapy from around the world. The primary goal of the conference is to facilitate the exchange of new scientific advancements, technological innovations, and clinical insights in the rapidly evolving field of cell and gene therapy. CARMA is a phase I/IIa clinical study evaluating the safety and efficacy of the CAR T-cell therapy ELC-301 in the treatment of patients with B-cell lymphoma. The study is divided into a dose-escalation phase (phase I) and a dose-expansion phase (phase IIa). Phase I primarily aims to establish the optimal dose and safety profile in up to 12 patients, while phase IIa will further evaluate the efficacy of the maximum tolerated dose in an additional six patients. CAR T-cells are a form of cell therapy created by genetically modifying a patient's T-cells to express a synthetic receptor (chimeric antigen receptor, CAR). This receptor is specifically designed to target a single tumor antigen--a molecule visible on the surface of cancer cells--and enables the T-cells to locate, bind to, and destroy the cancer cells. Annonce • Jan 21
Elicera Therapeutics Presents First Clinical Results from Itank-Armed Car T-Cell Therapy At Scientific Conference Elicera Therapeutics AB (publ) announced that the first patient in the CAR T-cell study CARMA, which evaluates the efficacy of ELC-301 against B-cell lymphoma, has been successfully treated. The one-month follow-up after treatment shows that the patient achieved a complete response with only very mild side effects. The treatment outcome will now be presented at the Cancer Crosslinks conference in Oslo on January 23. The purpose of the CARMA study is to identify the optimal dose for treatment with the iTANK-armed CAR T-cell therapy ELC-301, which will then be tested in an additional six patients during the phase IIa part of the study. The first patient showed a complete response (CR) at the first follow-up, one month after completing treatment, with no serious side effects observed. Two more patients will be treated with the lowest dose level in the first dosing group (cohort 1). Elicera intends to report structured and consolidated results from the study as each cohort is completed. These data are expected to be presented at scientific conferences in 2025 and 2026. The exact timeline for reporting cohort data depends on the study's progress and the timing of relevant conferences. Annonce • Nov 05
Elicera Therapeutics Includes the First Patient in the Phase I/II Clinical Study Carma Targeting B-Cell Lymphoma Elicera Therapeutics AB (publ) announced that the first patient has been enrolled in the company's Phase I/II clinical study, CARMA. The study aims to evaluate the iTANK-armed CAR T-cell therapy, ELC-301, in patients with hard-to-treat B-cell lymphoma, mantle cell lymphoma, or indolent lymphoma who have not responded to standard treatment or have experienced a relapse of the disease. The study will be conducted in two parts, with the initial phase involving dose escalation in 12 patients to determine the optimal dosing range for treatment with ELC-301. In the next phase, the maximum tolerable dose will be evaluated in an additional 6 patients, with a total of 12 patients expected to receive treatment at this dose level. The study is being conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge. According to the company's preliminary timeline, the dose escalation study, including 12 patients in total, is expected to be completed and reported in the second half of 2025. Data from the first dose group of three patients is expected to be reported in first quarter of 2025. Preliminary results from the second part of the study are anticipated approximately 6-12 months later. Following treatment, a follow-up period of at least two years will occur, meaning CARMA is expected to be completed and fully reported in 2028. CARMA is a single-arm, open-label multicenter study aiming to evaluate the safety profile and treatment efficacy of a single dose of ELC-301. It targets patients diagnosed with relapsed or refractory CD20-positive B-cell lymphoma, mantle cell lymphoma, or indolent lymphoma. The study will examine, among other things, the treatment's antitumor effect, toxicity, and tolerability. Elicera Therapeutics' drug candidate ELC-301 is a CAR T-cell therapy that targets CD20, a tumor antigen target expressed on B-cells, for the treatment of B-cell lymphoma, mantle cell lymphoma or indolent lymphoma. In addition to the direct cell-killing effect of CAR T-cells, they also express the immune-activating protein NAP, which is derived from a common bacterial species. In preclinical studies, the protein has been shown to be powerful in activating the body's own immune system against cancer, in parallel with the direct effect of the CAR T-cells, to effectively attack and kill tumor cells. The drug candidate has been armed with Elicera Therapeutics' technology platform iTANK. Annonce • Oct 24
Elicera Therapeutics AB (publ) Enrolls the Last Patient in the Clinical Phase I/II-Trial with Oncolytic Virus ELC-100 Elicera Therapeutics AB (publ) announced that the last patient has been enrolled in the clinical phase I/II study evaluating the company's oncolytic drug candidate ELC-100 (AdVince) against neuroendocrine tumors. The study's preliminary results are expected to be reported in the first half of 2025. The study, which is sponsored by Uppsala University, is carried out in two stages - a dose escalation study and a dose expansion study. The ongoing, first, dose escalation study primarily aims to evaluate the safety of the treatment in patients and identify the maximum tolerated dose (MTD). During the study, four dose levels are evaluated in three patients each. In addition to the primary goal of the dose escalation study, efficacy is also evaluated, for example the form of tumor response. The twelfth and last patient of the study has now been enrolled and initiated treatment. The preliminary study results are expected to be presented during the first half of 2025. Based on the outcome of the dose escalation study and subsequent outcome of discussions with regulatory authorities, the company will formulate a strategy for the continued clinical development of ELC-100. New Risk • Aug 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr28m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr28m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Market cap is less than US$10m (€6.03m market cap, or US$6.68m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr33m net loss in 2 years). Revenue is less than US$5m (kr12m revenue, or US$1.2m). New Risk • Apr 10
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 77% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr15m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (77% increase in shares outstanding). Market cap is less than US$10m (€3.71m market cap, or US$4.03m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr32m net loss in 3 years). Revenue is less than US$5m (kr11m revenue, or US$1.1m). Annonce • Mar 30
Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024 Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024, at 13:00 Central European Standard Time. Location: Advokatfirman Delphi Mäster Samuelsgatan 17 Stokholm Sweden New Risk • Mar 22
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr15m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings are forecast to decline by an average of 10% per year for the foreseeable future. Market cap is less than US$10m (€2.43m market cap, or US$2.62m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr32m net loss in 3 years). Revenue is less than US$5m (kr11m revenue, or US$1.1m). Annonce • Feb 17
Elicera Therapeutics AB (publ) to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1 Elicera Therapeutics AB announced that the company has been invited to present at the scientific conference International Society for Cell & Gene Therapy (ISCT) Meeting 2024 in Vancouver, Canada, May 28 to June 1. ISCT brings together leading researchers, clinicians and industry experts in cell and gene therapy from around the world. The main purpose of the conference is to promote the exchange of new scientific advances, technological advances and clinical insights in the rapidly developing field of cell and gene therapy. The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. Annonce • Feb 16
Elicera Therapeutics AB (Publ) Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301 Elicera Therapeutics AB (publ) received conditional approval from the Medical Products Agency on its CAR T-cell Clinical Trial Application to test ELC-301 (CARMA-study). In pace with nearing the start of the clinical Phase I/IIa study, see a clear need for strengthening the company's financial position. The company plan to report data from the first dosage group, consisting of three patients, already at the end of 2024 and complete results from all 12 patients in the second half of 2025. The project is financed by the Centre for Advanced Medical Products (CAMP) and is intended to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company have only one patient left to include in the dose-escalation study. In conjunction with the report, will provide a clearer description of the continued clinical development program. The company has developed a portfolio consisting of the patented iTANK gene technology platform and four drug candidates in clinical and preclinical development phase. This platform thus opens the door to new possibilities for treating solid tumors where current CAR T-cell therapies have not yet been successful. Elicera's business model is to develop and, over the long term, outlicense its in-house and patented arming technology iTANK and treatment methods for cancers. The strategy for generating revenue from commercial partnerships is built on: Conducting preclinical and clinical trials that demonstrate the mechanism of action and efficacy of the programs. Elicera has developed iTANK, a patented and commercially available platform technology for expanding the areas of application for CAR T-cell therapy. iTANK makes it possible to impact the microenvironment in solid tumors, activate a robust immune response against cancer and develop a long-term immunological memory related to several different tumor targets, which counteracts recurrences of cancer. All together, the results from the preclinical study support the possibilities of using Elicera's unique method to create CAR T-cell therapies against a range of solid forms of cancer - something that at present is very difficult. The results from the study were published in 2022 in Nature Biomedical Engineering1, one of the world's foremost scientific journals, and constitutes a fundamental pillar for the validity of the scientific concept and a cornerstone in dialogues with potential partners. The ELC-301 program is being developed to treat B-cell lymphoma. In the first half of 2024, Elicera expects to start a clinical Phase I/IIa trial, called the CARMA-study, with ELC-301 in patients with severe or recurring DLBCL. Since the study is open, the results may be presented after every dose group. The ELC-401 program is being developed to treat glioblastoma (GMB). In a preclinical study, the company was able to demonstrate that IL13Ra2 is an effective tumor target for CAR T-cells strengthened with iTANK. The results included the finding that the CAR T-cell had a potent cell-killing efficacy and prolonged survival in the disease model. As a next step in the development of ELC-401, clinical trials are planned for which Elicera is seeking soft financing and/or partnerships with other companies in order to conduct them. Alongside its CAR T-cell program and ELC-100, Elicera is developing ELC-201, a program to develop oncolytic virus treatment with the potential to treat several different forms of solid cancer. The company has extensively surveyed potential cancer indications for ELC-201 based on both scientific and commercial considerations, and is now evaluating alternatives for financing the program of clinical trials, with a focus on commercial partnership and various types of soft financing. ELC-100, also known as AdVince, is a program for developing and treating neuroendocrine tumors (NETs), which arise from cells in the neuroendocrine system.ELC-100 is currently undergoing a clinical Phase I/II trial (ClinicalTrials.gov identifier: NCT02749331) with Uppsala University as sponsor (agreements). Annonce • Feb 09
Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma Elicera Therapeutics AB (publ), announced that the company has received approval from the Swedish Medical Products Agency to start the clinical phase I/II study CARMA in patients with B-cell lymphoma that no longer respond to standard treatment or have relapsed. CARMA is a single-arm, unblinded, multicenter study that aims to evaluate the safety profile and treatment effect after one dose of ELC-301. It is carried out on patients diagnosed with difficult-to-treat CD20-positive B-cell lymphoma, mantle cell lymphoma or indolent lymphoma, or who have relapsed in the disease. Among other things, the study will examine the treatment's anti-tumor effect, toxicity and tolerability. The CARMA-study is carried out in two stages; a dose escalation phase (phase I) with a maximum of 12 patients, aimed at determining the optimal dose range, followed by a dose expansion phase (phase IIa) with a maximum of 6 patients receiving the maximum tolerated dose. A total of 12 patients are planned to be treated with the maximum tolerated dose. The study will be conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge. According to the company's preliminary timetable, the dose escalation study is expected to be completed and reported in the second half of 2025, and phase 2 is expected to be completed and reported approximately 6-12 months later. The full CARMA-study is expected to be completed and reported in 2027, after a follow-up period of at least two years. Annonce • Dec 23
Elicera Therapeutics AB (publ) Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research Elicera Therapeutics AB (publ) announced that its co-founder, Professor Magnus Essand, has received a total of 4.8 MSEK in funding from the Swedish Childhood Cancer Fund. The research project, which spans over three years, will be conducted by professor Magnus Essand's research group at Uppsala University and aims to investigate the ability of CAR T-cells to induce immunity in brain tumors in children. The research grant from the Swedish Childhood Cancer Fund is awarded to Uppsala University, and the results generated in the project will contribute to the understanding of whether Elicera's cell therapy candidate ELC-401 could also be used in the future to treat brain tumors in children. Annonce • Dec 22
Elicera Therapeutics AB (publ) Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application Elicera Therapeutics AB (publ) announced that it has submitted complementary data to the Swedish Medical Product Agency (MPA) that validates the GMP-level production standard of the CAR T-cell therapy ELC-301. The data package is submitted to meet the MPA’s request for additional information which was queried in its conditional approval of Elicera Therapeutic’s clinical Phase I/IIa study CARMA. In January 2023, Elicera Therapeutics submitted a Clinical Trial Application (CTA) to the MPA to conduct a clinical Phase I/IIa study (CARMA) aimed at evaluating the safety and efficacy of ELC-301, a CD20-directed iTANK-armed CAR T-cell therapy, in patients with relapsed and/or refractory B-cell malignancies. In April, the company received a conditional approval from the MPA, requesting complementary data to validate the production process of ELC-301 according to GMP standards. Elicera Therapeutics has now generated preclinical validation data, confirming high and consistent quality of its active pharmaceutical substance, and submitted the complementary information to the regulatory agency. The MPA will now review the data, for a period of maximum 14 weeks, and subsequently inform the company whether it can initiate the Phase I/IIa study CARMA or if additional data is needed. Elicera Therapeutic’s candidate therapy ELC-301 constitutes a fourth generation CAR T-cell therapy that targets the CD20 antigen, which is expressed on the cell surface of B-cell lymphoma cells. ELC-301 has been armed with iTANK to elicit a dual mode-of-action, partly via a direct cancer cell-killing effect by CAR T-cells, partly by activating the patients’ own killer T-cells against a wide array of target antigens. Thus, the patient’s killer T-cells are expected to target cancer cells independent of CD19 or CD20 expression. Annonce • Nov 01
Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024 Elicera Therapeutics AB (publ) announced that representatives of the largest owners have appointed the nomination committee ahead of the Annual General Meeting 2024. On May 10, the Annual General Meeting established rules to guide the work of the Nomination Committee. The three largest owners on September 30, 2023, were Magnus Essand, Di Yu and Jamal El-Mosleh, who together control 47.1% of the votes, and will be the election committee with Magnus Essand as chairman. New Risk • Oct 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr3.5m free cash flow). Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Revenue is less than US$1m (kr4.1m revenue, or US$369k). Market cap is less than US$10m (€5.43m market cap, or US$5.71m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr40m net loss in 2 years). Annonce • Jul 12
Elicera Therapeutics AB (publ) Receives Notice of Allowance for European Patent Protecting the iTANK Elicera Therapeutics AB (publ) announced that it has received a Communication EPC (Notice of Allowance) from the European Patent Office in its European patent application relating to the use of the iTANK[TM] technology in CAR T-cell therapies. The Communication means that the European Patent Office intends to grant the European patent application after the completion of certain formal steps. Once granted, the patent can be kept in force until 2036. New Risk • Jul 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.3m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 19% per year for the foreseeable future. Revenue is less than US$1m (kr2.3m revenue, or US$215k). Market cap is less than US$10m (€4.79m market cap, or US$5.23m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr45m net loss in 2 years). Annonce • Jan 27
Elicera Therapeutics AB (publ) Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma Elicera Therapeutics AB (publ) announced that it has submitted a Clinical Trial Application (CTA) to the Swedish Medical Products Agency and the Ethics Committee' to evaluate its CAR T-cell therapy, ELC-301, in treatment of B-cell lymphoma. The study aims to evaluate the safety and efficacy of one dose of CD20 directed CAR T-cells, armed with bystander immune activating properties, using the iTANK-platform, in patients with relapsed and/or refractory B-cell malignancies, by studying tolerance, toxicity, biological effects, and anti-tumor responses. The study design proposes conducting the study in two stages: a dose escalation stage to minimize the risk of serious side effects and to identify the appropriate testing dosage, followed by treatment of the remaining patients with the maximum tolerable dose. More information on study design will be presented upon approval of the CTA.Elicera's drug candidate, ELC-301, constitutes a fourth generation CAR T-cell therapy that targets the CD20 antigen which, like CD19, is expressed on all B-cell lymphoma cells. ELC-301 is armed with Elicera's iTANK-technology platform to elicit a dual mode-of-action and a broad attack on cancer by also activating the patients' own killer T-cells against the whole set of relevant antigen targets on tumor cells, not only against CD19 or CD20. Development and preparations for the ELC-301 study have been aided over the past year by grants from the European Innovation Council (EIC) Accelerator Programme and Vinnova. In combination with existing cash, the EU-funding was sufficient to fully fund the study and the Vinnova grant will to be used to develop an automated CAR T-cell manufacturing process to be implemented as Good Manufacturing Practice . Annonce • Jan 24
Elicera Therapeutics AB (publ) Continues Phase I/IIa Study with Oncolytic Virus as Planned, Following Safety Review in Cohort 3 Elicera Therapeutics AB (publ) announced that the Data Safety and Monitoring Board (DSMB) completed its third assessment of the ongoing clinical phase I/IIa study with oncolytic virus, ELC-100, in neuroendocrine tumors and recommended continuation of the trial, as planned. The dose escalation study, which is carried out in collaboration with Uppsala University as sponsor, has previously been able to report signals of clinical activity in two of eight evaluable patients in the ELC-100 study, where a total of 12 patients are planned to be treated in four dose levels/cohorts. After the DSMB's recommendation to continue the trial, recruitment of the remaining three patients in the last cohort can commence. Annonce • Dec 16
Elicera Therapeutics AB (publ) Announces Positive Clinical Effect in Cancer Trial Elicera Therapeutics AB (publ) recently participated at the Oncolytic Virotherapy Summit in Boston, where the immuno-oncology company presented positive data regarding ELC-100. Clinical activity in the form of a reduction in metastases has now been observed in two of the eight patients evaluated so far, providing some support for the candidate's potential in neuroendocrine tumours (NET). Annonce • Dec 08
Elicera Therapeutics Reports Additional Signals of Clinical Activity in Patients Treated for Neuroendocrine Tumors in the Elc-100 Study At the Oncolytic Virotherapy Summit in Boston Elicera Therapeutics AB (publ) announced that two of a total of eight patients so far fully treated and evaluated in the ongoing phase I/IIa study, which evaluates the oncolytic virus ELC-100 for the treatment of neuroendocrine tumors, have shown signs of clinical activity by reducing the size of some metastases. Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chief Science Officer, Co-Founder & Director Magnus Essand is the most experienced director on the board, commencing their role in 2014. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annonce • Jun 02
Elicera Therapeutics AB (publ) Receives EUR 2.5 Million Funding to Fully Finance Clinical Phase I/II-Trial with its Car T-Cell Therapy, ELC-301 Elicera Therapeutics AB (publ) has been awarded EUR 2.5 million funding from the European Innovation Council (EIC) Accelerator Programme. The grant is sufficient to fully fund Elicera's planned clinical phase I/II-study evaluating its CAR T-cell therapy ELC-301 in the treatment of B-cell lymphoma. Despite relatively high response rates of market-approved CAR T-cell therapies targeting the CD19 protein, there remains a high unmet medical need for these patients. The majority of patients treated with CD19 CAR T-cell therapies are either resistant to treatment or relapse within 12 months and have then often lost the CD19 target antigen on the recurring tumors. Elicera's drug candidate, ELC-301, constitutes a fourth generation CAR T-cell therapy that targets the CD20 protein which, like CD19, is expressed on all B-cell lymphoma cells. ELC-301 is armed with Elicera's iTANK-technology platform to elicit a dual mode-of-action and a broad attack on cancer by also activating the patients' own killer T-cells against the whole set of relevant antigen targets on tumor cells, not only CD19 or CD20. The EIC Accelerator award supports individual Small and Medium Enterprises (SMEs), in particular start-ups and spinout companies to develop and scaleup game-changing innovations in the EU. Competition is ferocious and less than 5% of all EIC applications are awarded. Annonce • Apr 28
Elicera Therapeutics Successfully Concludes Preclinical Proof-Of-Concept Studies for Oncolytic Virus ELC-201 Confirming the Proposed Mode-Of-Action Elicera Therapeutics AB announced it has concluded preclinical proof-of-concept studies for its oncolytic virus ELC-201. The study results confirm ELC-201's proposed mode-of-action. ELC-201 is a next-generation oncolytic virus that has been genetically modified to enable treatment of most cancers. The drug candidate has been armed with Elicera's proprietary platform technology, iTANK, to elicit a parallel immune response and attack on cancer cells by the patients' own endogenous killer T-cells. In addition, ELC-201 is armed with yet another immune stimulating factor, 4-1BBL, to further amplify the anti-cancer immune response. Preclinical studies, including data from pancreatic cancer animal models, show that ELC-201: Effectively infiltrates and kills tumor cells. Effectively induces a parallel (bystander) immune response and boosts the function of tumor infiltrating immune cells. Better controls tumor growth and increases survival in comparison to placebo. Better controls tumor growth and increases survival in comparison to the same oncolytic virus but without iTANK and 4-1BBL arming. Board Change • Apr 27
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chief Science Officer, Co-Founder & Director Magnus Essand is the most experienced director on the board, commencing their role in 2014. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Dec 31
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Chief Science Officer, Co-Founder & Director Magnus Essand is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Annonce • Dec 16
Elicera Therapeutics AB (publ) Enters into Agreement with Baylor College of Medicine for Contract Manufacturing of Next Generation Oncolytic Virus, ELC-201 Elicera Therapeutics AB (publ) announced that it has signed an agreement with Baylor College of Medicine (BCM), Center for Cell & Gene Therapy regulating contract manufacturing of ELC-201, the company's next generation oncolytic virus armed with Elicera's fully developed iTANK-platform for a multi-targeted attack on cancer. This is the second collaboration between Elicera and Baylor College of Medicine (BCM), Center for Cell & Gene Therapy, a private health sciences center in Houston, Texas, for production of oncolytic viruses. BCM's production of ELC-201 will be performed according to Good Manufacturing Practice (GMP) and is planned to be completed by mid 2023. The viral vectors will be used in Elicera's upcoming clinical phase I/II-study with ELC-201. 
